News

Latest initiative will focus on providing hospitals and trial sponsors with streamlined access to unstructured healthcare data and the role of AI.

EHR-to-EDC projects - including MSK’s collaboration with IgniteData and leading sponsors - are sparking a new wave of cross-industry collaboration.

With more trials, more data points, more complex criteria for suitable patients, here are six of the perennial challenges clinical trial researchers typically face.

What are some of the points to look out for if you’re considering implementing a solution to support EHR-to-EDC data transfer? Compare options.

Widely respected as one of the leading minds in healthcare technology, Steve has a stellar track record in healthcare innovation and investment.

Four things that can transform clinical trials - Joseph Lengfellner outlines 4 exciting new and emerging solutions to the challenges of running clinical trials.

Joseph Lengfellner, Senior Director, Clinical Research Informatics at Memorial Sloan Kettering Cancer Center (MSK)) on the biggest challenges facing clinical trials.

IgniteData’s CTO, Richard Yeatman, talks structured data and its value to clinical trials, as well as approaches to and challenges of re-using unstructured data

IgniteData’s data transfer technology, Archer, could map 100% of Vital Signs and Labs data, and successfully transfer 100% of mapped data from EHR-to-EDC.

MSK Innovation Hub and IgniteData project signals substantive move away from laborious data transcription in cancer studies.

Data mapping in clinical trials ensures that data taken from sites' EHR are transferred to a sponsor's EDC in a way that is accepted and recognised.

The time is truly ripe for us to realise the many benefits that can come from streamlining the transfer of EHR data into clinical trials – also known as EHR-to-EDC.

Suki Balendra PhD talks through the UK clinical trial landscape from the viewpoint and priorities of the government, the NIHR, research sites & industry.

Qin Ye, a principal at ZS, tells us more about his background, and shares insights on trends, innovation in life sciences and the outlook for clinical trial data.